Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 9Thoracic 1Sarcoma 1NET 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Neuroendocrine Tumors 34Pheochromocytoma 14Thyroid Neoplasms 11Pituitary Neoplasms 11Carcinoma, Neuroendocrine 10Adrenocortical Carcinoma 10Thyroid Cancer, Papillary 9Paraganglioma 8Sarcoma 7Adrenal Gland Neoplasms 7Small Cell Lung Carcinoma 6Neuroblastoma 6Cushing Syndrome 6Parathyroid Neoplasms 5Neoplasms 5Carcinoma, Medullary 5Carcinoid Tumor 5Pancreatic Neoplasms 4Ovarian Neoplasms 4Osteosarcoma 4Multiple Endocrine Neoplasia Type 1 4Meningioma 4Insulinoma 4Cholangiocarcinoma 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 4Adenoma, Islet Cell 4Adenocarcinoma, Follicular 4Thyroid Carcinoma, Anaplastic 3

Interventions

cabozantinib 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Clear-cell metastatic renal cell carcinoma × Endocrine × 30 days × Clear all
NCT05263050 2026-05-22

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Fox Chase Cancer Center

Phase 2 Recruiting
111 enrolled
EndocrineGenitourinaryNET

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡